ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis

Kuo Liang Chiu, Yu Sen Lin, Ting Ting Kuo, Chia Chien Lo, Yu Kai Huang, Hsien Fang Chang, Eric Y. Chuang, Ching Chan Lin, Wei Chung Cheng, Yen Nien Liu, Liang Chuan Lai, Yuh Pyng Sher

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

MicroRNAs (miRNAs), which are endogenous short noncoding RNAs, can regulate genes involved in important biological and pathological functions. Therefore, dysregulation of miRNAs plays a critical role in cancer progression. However, whether the aberrant expression of miRNAs is regulated by oncogenes remains unclear. We previously demonstrated that a disintegrin and metalloprotease domain 9 (ADAM9) promotes lung metastasis by enhancing the expression of a pro-migratory protein, CUB domain containing protein 1 (CDCP1). In this study, we found that this process occurred via miR-1 down-regulation. miR-1 expression was down-regulated in lung tumors, but increased in ADAM9-knockdown lung cancer cells, and was negatively correlated with CDCP1 expression as well as the migration ability of lung cancer cells. Luciferase-based reporter assays showed that miR-1 directly bound to the 3'-untranslated region of CDCP1 and inhibited its translation. Treatment with a miR-1 inhibitor restored CDCP1 protein levels and enhanced tumor cell mobility. Overexpression of miR-1 decreased tumor metastases and increased the survival rate in mice. ADAM9 knockdown reduced EGFR signaling and increased miR-1 expression. These results revealed that ADAM9 down-regulates miR-1 via activating EGFR signaling pathways, which in turn enhances CDCP1 expression to promote lung cancer progression.

Original languageEnglish
Pages (from-to)47365-47378
Number of pages14
JournalOncotarget
Volume8
Issue number29
DOIs
Publication statusPublished - 2017

Fingerprint

Disintegrins
Metalloproteases
Lung Neoplasms
Neoplasm Metastasis
MicroRNAs
Neoplasms
Down-Regulation
Small Untranslated RNA
Lung
3' Untranslated Regions
Luciferases
Oncogenes
Proteins
Protein Domains
Genes

Keywords

  • ADAM9
  • CDCP1
  • EGFR
  • Lung cancer
  • MiR-1

ASJC Scopus subject areas

  • Oncology

Cite this

Chiu, K. L., Lin, Y. S., Kuo, T. T., Lo, C. C., Huang, Y. K., Chang, H. F., ... Sher, Y. P. (2017). ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. Oncotarget, 8(29), 47365-47378. https://doi.org/10.18632/oncotarget.17648

ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. / Chiu, Kuo Liang; Lin, Yu Sen; Kuo, Ting Ting; Lo, Chia Chien; Huang, Yu Kai; Chang, Hsien Fang; Chuang, Eric Y.; Lin, Ching Chan; Cheng, Wei Chung; Liu, Yen Nien; Lai, Liang Chuan; Sher, Yuh Pyng.

In: Oncotarget, Vol. 8, No. 29, 2017, p. 47365-47378.

Research output: Contribution to journalArticle

Chiu, KL, Lin, YS, Kuo, TT, Lo, CC, Huang, YK, Chang, HF, Chuang, EY, Lin, CC, Cheng, WC, Liu, YN, Lai, LC & Sher, YP 2017, 'ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis', Oncotarget, vol. 8, no. 29, pp. 47365-47378. https://doi.org/10.18632/oncotarget.17648
Chiu, Kuo Liang ; Lin, Yu Sen ; Kuo, Ting Ting ; Lo, Chia Chien ; Huang, Yu Kai ; Chang, Hsien Fang ; Chuang, Eric Y. ; Lin, Ching Chan ; Cheng, Wei Chung ; Liu, Yen Nien ; Lai, Liang Chuan ; Sher, Yuh Pyng. / ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. In: Oncotarget. 2017 ; Vol. 8, No. 29. pp. 47365-47378.
@article{b6f0ecdb2c3944c994b1dbafb9aad75e,
title = "ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis",
abstract = "MicroRNAs (miRNAs), which are endogenous short noncoding RNAs, can regulate genes involved in important biological and pathological functions. Therefore, dysregulation of miRNAs plays a critical role in cancer progression. However, whether the aberrant expression of miRNAs is regulated by oncogenes remains unclear. We previously demonstrated that a disintegrin and metalloprotease domain 9 (ADAM9) promotes lung metastasis by enhancing the expression of a pro-migratory protein, CUB domain containing protein 1 (CDCP1). In this study, we found that this process occurred via miR-1 down-regulation. miR-1 expression was down-regulated in lung tumors, but increased in ADAM9-knockdown lung cancer cells, and was negatively correlated with CDCP1 expression as well as the migration ability of lung cancer cells. Luciferase-based reporter assays showed that miR-1 directly bound to the 3'-untranslated region of CDCP1 and inhibited its translation. Treatment with a miR-1 inhibitor restored CDCP1 protein levels and enhanced tumor cell mobility. Overexpression of miR-1 decreased tumor metastases and increased the survival rate in mice. ADAM9 knockdown reduced EGFR signaling and increased miR-1 expression. These results revealed that ADAM9 down-regulates miR-1 via activating EGFR signaling pathways, which in turn enhances CDCP1 expression to promote lung cancer progression.",
keywords = "ADAM9, CDCP1, EGFR, Lung cancer, MiR-1",
author = "Chiu, {Kuo Liang} and Lin, {Yu Sen} and Kuo, {Ting Ting} and Lo, {Chia Chien} and Huang, {Yu Kai} and Chang, {Hsien Fang} and Chuang, {Eric Y.} and Lin, {Ching Chan} and Cheng, {Wei Chung} and Liu, {Yen Nien} and Lai, {Liang Chuan} and Sher, {Yuh Pyng}",
year = "2017",
doi = "10.18632/oncotarget.17648",
language = "English",
volume = "8",
pages = "47365--47378",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "29",

}

TY - JOUR

T1 - ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis

AU - Chiu, Kuo Liang

AU - Lin, Yu Sen

AU - Kuo, Ting Ting

AU - Lo, Chia Chien

AU - Huang, Yu Kai

AU - Chang, Hsien Fang

AU - Chuang, Eric Y.

AU - Lin, Ching Chan

AU - Cheng, Wei Chung

AU - Liu, Yen Nien

AU - Lai, Liang Chuan

AU - Sher, Yuh Pyng

PY - 2017

Y1 - 2017

N2 - MicroRNAs (miRNAs), which are endogenous short noncoding RNAs, can regulate genes involved in important biological and pathological functions. Therefore, dysregulation of miRNAs plays a critical role in cancer progression. However, whether the aberrant expression of miRNAs is regulated by oncogenes remains unclear. We previously demonstrated that a disintegrin and metalloprotease domain 9 (ADAM9) promotes lung metastasis by enhancing the expression of a pro-migratory protein, CUB domain containing protein 1 (CDCP1). In this study, we found that this process occurred via miR-1 down-regulation. miR-1 expression was down-regulated in lung tumors, but increased in ADAM9-knockdown lung cancer cells, and was negatively correlated with CDCP1 expression as well as the migration ability of lung cancer cells. Luciferase-based reporter assays showed that miR-1 directly bound to the 3'-untranslated region of CDCP1 and inhibited its translation. Treatment with a miR-1 inhibitor restored CDCP1 protein levels and enhanced tumor cell mobility. Overexpression of miR-1 decreased tumor metastases and increased the survival rate in mice. ADAM9 knockdown reduced EGFR signaling and increased miR-1 expression. These results revealed that ADAM9 down-regulates miR-1 via activating EGFR signaling pathways, which in turn enhances CDCP1 expression to promote lung cancer progression.

AB - MicroRNAs (miRNAs), which are endogenous short noncoding RNAs, can regulate genes involved in important biological and pathological functions. Therefore, dysregulation of miRNAs plays a critical role in cancer progression. However, whether the aberrant expression of miRNAs is regulated by oncogenes remains unclear. We previously demonstrated that a disintegrin and metalloprotease domain 9 (ADAM9) promotes lung metastasis by enhancing the expression of a pro-migratory protein, CUB domain containing protein 1 (CDCP1). In this study, we found that this process occurred via miR-1 down-regulation. miR-1 expression was down-regulated in lung tumors, but increased in ADAM9-knockdown lung cancer cells, and was negatively correlated with CDCP1 expression as well as the migration ability of lung cancer cells. Luciferase-based reporter assays showed that miR-1 directly bound to the 3'-untranslated region of CDCP1 and inhibited its translation. Treatment with a miR-1 inhibitor restored CDCP1 protein levels and enhanced tumor cell mobility. Overexpression of miR-1 decreased tumor metastases and increased the survival rate in mice. ADAM9 knockdown reduced EGFR signaling and increased miR-1 expression. These results revealed that ADAM9 down-regulates miR-1 via activating EGFR signaling pathways, which in turn enhances CDCP1 expression to promote lung cancer progression.

KW - ADAM9

KW - CDCP1

KW - EGFR

KW - Lung cancer

KW - MiR-1

UR - http://www.scopus.com/inward/record.url?scp=85024387492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024387492&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.17648

DO - 10.18632/oncotarget.17648

M3 - Article

AN - SCOPUS:85024387492

VL - 8

SP - 47365

EP - 47378

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -